PharmaGap starts drug trials at OHRI

OTTAWA – PharmaGap Inc.’s lead cancer drug begins testing at the Ottawa Hospital Research Institute. As announced by the firm in March, the institute will evaluate the effects of PhG-alpha-1 drug PharmaGap-logo-122X25.JPGon nine ovarian cancer cell lines. The drug is also currently being tested at Maryland’s National Cancer Institute, and was previously assessed at New York’s Memorial Sloan Kettering Cancer Center, as well as in PharmaGap’s own labs. “Combined with expected results from testing at the NCI and with all previous test programs completed, we hope to see conclusive, independently derived proof of efficacy for PhG-alpha-1 that will attract the attention of both the pharmaceutical industry and the investment community in Canada and the United States,” says PharmaGap CEO Robert McInnis. Click here for more information.

Submit a comment

Please leave your name, which will be used to sign your submission to the SCANsite. Thanks for contributing your thoughts. Come back again. Tony Patterson, Editor & CEO.

© 2006 - 2009 SCAN
INTEGRITY INTELLIGENCE INFORMATION
Site by Citadel Rock
SCAN